Centenial Surgical Peer Comparison

BSE: 531380

₹71.96

₹0.71 (1.00%)

As on 02-Nov-2026IST

Market cap

₹26 Cr

Revenue (TTM)

₹56 Cr

P/E Ratio

--

P/B Ratio

1

Div. Yield

0 %

Edit

	Centenial Surgical	Gland Pharma	Medplus Health	Laxmi Dental	Shree Pacetronix
Market cap (₹ Cr)	26	52,148	7,170	1,002	64
Revenue (₹ Cr)	56	6,725	7,587	287	21
Net Profit (₹ Cr)	-1.45	1,128.79	211.00	28.67	3.24
Net Margin (%)	-2.56	16.02	2.75	9.68	15.18
RoE (%)	-4.88	11.51	10.44	9.14	19.12
Price to Earnings	--	46.20	33.97	32.43	19.93
Price-To-Book	0.95	4.91	3.47	4.08	3.47

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Centenial Surgical	Gland Pharma	Medplus Health	Laxmi Dental	Shree Pacetronix
Operating Revenue	53.52	5,616.50	6,136.05	239.11	16.80
Total Income	53.64	5,830.11	6,184.67	242.45	16.93
Total Expenditure	47.10	4,347.58	5,632.59	196.46	14.47
EBITDA	6.42	1,268.92	503.47	42.65	2.34
Depreciation	4.25	377.87	249.84	15.02	0.81
EBIT	2.16	891.05	253.62	27.63	1.53
Interest	3.90	42.00	118.95	6.17	0.61
Other Income	0.12	213.61	48.62	3.34	0.12
Exceptional Items	--	--	--	7.03	--
Profit before Tax	-1.62	1,062.66	183.29	31.83	1.04
Provision for Tax	-0.15	364.13	33.06	6.45	0.29
Profit after Tax	-1.46	698.53	150.23	25.38	0.75

Liabilities (₹ Cr)

	Centenial Surgical	Gland Pharma	Medplus Health	Laxmi Dental	Shree Pacetronix
Shareholder's Funds	30.75	9,150.74	1,740.56	208.54	13.78
Minority Interest	--	--	-0.66	0.16	0.00
Non-Current Liabilities	21.97	457.27	991.72	12.82	-0.07
Current Liabilities	31.83	1,564.85	624.57	56.70	8.87
Total Liabilities	84.58	11,172.85	3,456.02	284.67	23.05

Assets (₹ Cr)

	Centenial Surgical	Gland Pharma	Medplus Health	Laxmi Dental	Shree Pacetronix
Non-Current Assets	21.59	4,389.91	1,464.69	91.16	5.39
Current Assets	62.96	6,782.94	1,891.49	187.06	17.19
Total Assets	84.58	11,172.85	3,456.02	284.67	23.05
Total Debt*	12.26	269.21	0.00	11.37	5.07
Net Current Assets	31.13	5,218.09	1,266.92	130.35	8.32
Contingent Liabilities	0.10	21.38	13.78	0.60	0.42

Cashflow (₹ Cr)

	Centenial Surgical	Gland Pharma	Medplus Health	Laxmi Dental	Shree Pacetronix
Cash From Operating Activities	17.07	914.73	540.43	43.83	-0.01
Cash Flow from Investing Activities	-11.61	1,704.74	-317.61	-29.24	-0.04
Cash from Financing Activities	-5.93	-433.48	-227.98	110.64	0.19
Net Cash Inflow / Outflow	-0.47	2,185.99	-5.16	125.23	0.14

Ratios

Profitability Ratios

	Centenial Surgical	Gland Pharma	Medplus Health	Laxmi Dental	Shree Pacetronix
ROCE (%)	5.09	11.97	18.22	24.97	9.13
ROE (%)	-4.93	7.82	9.21	21.40	5.59
ROA (%)	-1.79	6.41	4.73	12.64	3.42
EBIT Margin (%)	12.22	26.40	9.00	19.23	14.64
Net Margin (%)	-2.73	11.98	2.43	10.47	4.43
Cash Profit Margin (%)	5.22	19.16	6.43	16.89	9.27

Growth Ratios

	Centenial Surgical	Gland Pharma	Medplus Health	Laxmi Dental	Shree Pacetronix
Revenue Growth (%)	4.55	-0.85	9.09	23.53	-23.76
EBIT Growth (%)	23.91	-1.38	34.23	76.27	-59.17
Net Profit Growth (%)	-229.03	-9.57	129.09	41.44	-77.67
EPS Growth (%)	-229.03	-9.60	129.29	-35.33	-77.67
Book Value Growth (%)	-4.81	4.91	10.77	569.07	5.75

Valuation Ratios

	Centenial Surgical	Gland Pharma	Medplus Health	Laxmi Dental	Shree Pacetronix
Price / Earnings	0.00	37.55	60.48	76.82	29.91
Price / Book Value	1.38	2.87	5.30	11.83	1.63
Dividend Yield (%)	0.00	1.13	0.00	0.00	0.00
EV/EBITDA	7.98	16.15	15.80	50.94	10.73
Market Cap (₹ Cr)	40.13	26,233.01	9,091.18	2,440.49	22.43

Solvency Ratios

	Centenial Surgical	Gland Pharma	Medplus Health	Laxmi Dental	Shree Pacetronix
Debt to Equity	0.40	0.03	0.00	0.06	0.37
Short term debt to equity ratio	0.40	--	--	0.56	0.33
Current Ratio	1.98	4.33	3.03	3.30	1.94
Quick Ratio	0.61	3.26	0.87	2.97	1.15
Interest Coverage	0.59	26.30	2.54	6.16	2.71

Operating Efficiency Ratios

	Centenial Surgical	Gland Pharma	Medplus Health	Laxmi Dental	Shree Pacetronix
Debtors to sales (%)	34.38	27.00	0.22	15.34	39.46
Asset Turnover	0.65	0.52	1.96	1.19	0.77
Receivable days	126.86	99.92	0.90	47.00	122.59
Inventory Days	293.26	108.54	78.76	33.10	138.71
Payable days	178.88	138.65	21.71	152.61	36.89
Cash Conversion Cycle	241.25	69.81	57.95	-72.51	224.42

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly